Lifog

Latanoprost, the active ingredient in Lifog, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is indicated for the management of primary open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Lifog as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across EU and global markets. The company manages end‑to‑end logistics, documentation and post‑market support for its ophthalmic products, including temperature‑controlled shipping where required.

Latanoprost acts on the ocular outflow pathway to reduce intra‑ocular pressure in glaucoma‑related conditions.

- Primary open-angle glaucoma: lowers intra‑ocular pressure to slow progression of optic nerve damage. - Ocular hypertension: reduces pressure to prevent development of glaucoma. - Secondary open-angle glaucoma: improves fluid outflow to control pressure.

Latanoprost may cause ocular and systemic reactions, most of which are mild and transient.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Itching or irritation: transient ocular discomfort. - Increased eyelash growth: longer, thicker lashes. - Darkening of iris: gradual increase in brown pigmentation.

Serious or Rare Side Effects: - Ocular inflammation: uveitis or iritis requiring medical attention. - Severe eye pain with vision loss: possible hypotony or corneal edema. - Allergic reaction: swelling, rash, or anaphylaxis.

Before initiating Lifog, clinicians should evaluate patient history and monitor ocular status regularly.

- Assess intra‑ocular pressure: confirm elevated pressure before use. - Screen for active ocular infection or inflammation: avoid during uveitis. - Caution in corneal disorders: monitor for epithelial changes. - Evaluate pregnancy and lactation status: safety unknown, use only if benefit outweighs risk. - Review concomitant ocular medications: avoid additive irritation. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents, altering efficacy or tolerability.

Major Interactions (Avoid): - Concurrent use of other prostaglandin analogues: may cause excessive IOP lowering and hypotony. - Combination with ocular anesthetics containing preservatives: increased risk of ocular irritation. - Systemic carbonic anhydrase inhibitors: may diminish IOP‑lowering effect.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive pressure‑lowering effect, monitor IOP. - Alpha‑agonist eye drops: potential synergistic effect, adjust dosing if needed. - Systemic NSAIDs: may interfere with prostaglandin pathway, observe response.